37482-64-7

Basic information

• Product Name: 2-Chloro-4-ethoxy-6-methyl-pyrimidine
• Synonyms: 2-Chloro-4-ethoxy-6-methyl-pyrimidine
• CAS NO: 37482-64-7
• Molecular Formula: C₇H₉ClN₂O
• Molecular Weight: 173
• EINECS: 604-604-1
• Mol File: 37482-64-7.mol
• Article Data: 5

Chemical Properties

• Melting Point: 70-73℃
• Boiling Point: 282℃
• Flash Point: 124℃
• Appearance: /
• Density: 1.193
• CAS DataBase Reference: 2-Chloro-4-ethoxy-6-methyl-pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-4-ethoxy-6-methyl-pyrimidine(37482-64-7)
• EPA Substance Registry System: 2-Chloro-4-ethoxy-6-methyl-pyrimidine(37482-64-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 37482-64-7(Hazardous Substances Data)

Usage

Description

2-Chloro-4-ethoxy-6-methyl-pyrimidine is an organic compound characterized by its pyrimidine ring structure, which features a chlorine atom at the 2nd position, an ethoxy group at the 4th position, and a methyl group at the 6th position. 2-Chloro-4-ethoxy-6-methyl-pyrimidine is known for its potential applications in the pharmaceutical and chemical industries due to its unique chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
2-Chloro-4-ethoxy-6-methyl-pyrimidine is used as a reactant or starting material for the preparation of azolylpyrimidines. These azolylpyrimidines are cytoprotective antiulcer agents, which means they have the potential to protect the lining of the stomach and intestines, helping to prevent or treat ulcers. 2-Chloro-4-ethoxy-6-methyl-pyrimidine's reactivity and structural features make it a valuable building block in the synthesis of these therapeutic agents.

Upstream product

• 5424-21-5 2,4-dichloro-6-methylpyrimidine 
• 64-17-5 ethanol 
• 141-52-6 sodium ethanolate 

Relevant articles and documents

Optimization of pyrimidinol antioxidants as mitochondrial protective agents: ATP production and metabolic stability

Previously we described a novel series of pyrimidinol antioxidants and their structural optimization as potential therapeutic agents for neurodegenerative and mitochondrial disorders. Our initial lead compound was a potent antioxidant in vitro, but was subsequently found to exhibit poor stability to oxidative metabolism. The current study focused on balancing potency with metabolic stability through structural modification, and involved modifications at positions 2 and 4 of the pyrimidinol redox core, likely sites of oxidative metabolism. Eight new analogues have been prepared and their ability to suppress lipid peroxidation and reactive oxygen species (ROS), and to preserve mitochondrial membrane potential (Δψm) and support ATP production, has been investigated. The metabolic stability of the prepared compounds was also assessed in vitro using bovine liver microsomes to obtain preliminary insight on this class of compounds. This study revealed the complexity of balancing reasonable metabolic stability with efficient antioxidant properties. While a few analogues appear promising, especially in terms of metabolic stability, a 4-isopropoxy derivative conserved the favorable biological activity and exhibited good metabolic stability. The favorable metabolic stability conferred by the combination of the azetidine and isopropoxy moieties in analogue 6 makes this compound an excellent candidate for further evaluation.

ANTIVIRAL COMPOUNDS

The invention is provides novel antiviral compounds, as well as derivatives thereof. The compounds of the invention are preferably formulated as pharmaceuticals. The invention provides the compounds for use in the prevention and treatment of infectious diseases, in particular viral diseases. In some aspects the invention is based on the antiviral activity of the provided compounds against the Chikungunya virus, and hence, their application in the treatment or prevention of any physiological manifestation of such viral infection.

THERAPEUTIC COMPOUNDS

Compounds of formula (I) and salts are disclosed. Also disclosed are isotopes of compounds of formula I of the salts thereof. Pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods using a compound of formula I are disclosed.